BCTXW (BriaCell Therapeutics) OCF Yield %: -112.40 (As of Jun. 29, 2026)


BCTXW BriaCell Therapeutics Corp BCTXW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics OCF Yield %?

BriaCell Therapeutics BCTXW 23 OCF Yield % is -112.40 as of Jun. 29, 2026. GuruFocus rates BCTXW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, BriaCell Therapeutics ranks worse than 91.67% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, BriaCell Therapeutics's Trailing 12-Month Cash Flow from Operations is $-30.82 Mil, and Market Cap is $0.00 Mil. Therefore, BriaCell Therapeutics's OCF Yield % for today is -112.40%.

The historical rank and industry rank for BriaCell Therapeutics's OCF Yield % or its related term are showing as below:

BCTXW' s OCF Yield % Range Over the Past 10 Years
Min: -112.4   Med: 0   Max: -112.4
Current: -112.4


During the past 13 years, the highest OCF Yield % of BriaCell Therapeutics was -112.40%. The lowest was -112.40%. And the median was %.

BCTXW's OCF Yield % is ranked worse than
91.67% of 1416 companies
in the Biotechnology industry
Industry Median: -8.23 vs BCTXW: -112.40

BriaCell Therapeutics's OCF Margin % for the quarter that ended in Apr. 2026 was %.


BriaCell Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


BriaCell Therapeutics OCF Yield % Related Terms


BriaCell Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics OCF Yield % Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCTXW vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, BriaCell Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's OCF Yield % falls into.


BCTXW
23GF Score
BriaCell Therapeutics Corp BCTXW
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

BriaCell Therapeutics's OCF Yield % for the fiscal year that ended in Jul. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-28.171 /
=N/A%

BriaCell Therapeutics's annualized OCF Yield % for the quarter that ended in Apr. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-7.02 * 4 /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -112.40 mean?
BriaCell Therapeutics (BCTXW) has a OCF Yield % of -112.40 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BriaCell Therapeutics and its competitors. According to the industry distribution chart, BriaCell Therapeutics ranks #1298 out of 1416 companies in the Biotechnology industry, placing it in the top 91.7%.
Is BriaCell Therapeutics' OCF Yield % too high?
BriaCell Therapeutics' current OCF Yield % is -112.40. Based on the distribution chart, BriaCell Therapeutics ranks #1298 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BriaCell Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BriaCell Therapeutics ranks #1298 out of 1416 companies for OCF Yield %. This places BriaCell Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current OCF Yield % is -112.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current OCF Yield % of -112.40. The current OCF Yield % is -112.40. BriaCell Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current OCF Yield % is -112.40 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
23GF Score

Get the complete analysis for BCTXW

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price